Clicky

Valneva SE(VALN) News

Date Title
Jun 26 Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus
Jun 25 Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance
Jun 6 Valneva reports data from Phase II chikungunya vaccine trial in children
Jun 5 Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®
Jun 5 [Valneva SE] Declaration of shares and voting rights - May 2025
Jun 4 Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update
May 12 Valneva’s chikungunya vaccine use halted in older adults amid safety concerns
May 12 Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States
May 9 Eli Lilly extends Purdue alliance; EMA investigates Valneva shot
May 8 Valneva SE (INRLF) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Operational ...
May 7 VALNEVA Declaration of shares and voting rights: April 30, 2025
May 7 Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly
May 7 Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Apr 10 VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study
Apr 9 Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
Apr 8 Exploring Three High Growth Tech Stocks In Europe
Jan 3 VALNEVA Declaration of shares and voting rights: December 31, 2024
Oct 4 Valneva SE - Declaration of shares and voting rights - September 30, 2024
Oct 3 Valneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET
Aug 6 VALNEVA - Declaration of shares and voting rights: July 31, 2024